234 related articles for article (PubMed ID: 22956577)
21. Cell-mediated lysis of tumor targets directed by murine monoclonal antibodies of IgM and all IgG isotypes.
Ralph P; Nakoinz I
J Immunol; 1983 Aug; 131(2):1028-31. PubMed ID: 6134771
[TBL] [Abstract][Full Text] [Related]
22. Macrophages are the dominant effector cells responsible for IgG-mediated passive systemic anaphylaxis challenged by natural protein antigen in BALB/c and C57BL/6 mice.
Jiao D; Liu Y; Lu X; Liu B; Pan Q; Liu Y; Liu Y; Zhu P; Fu N
Cell Immunol; 2014; 289(1-2):97-105. PubMed ID: 24751884
[TBL] [Abstract][Full Text] [Related]
23. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
24. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
Roberts MR; Cooke KS; Tran AC; Smith KA; Lin WY; Wang M; Dull TJ; Farson D; Zsebo KM; Finer MH
J Immunol; 1998 Jul; 161(1):375-84. PubMed ID: 9647246
[TBL] [Abstract][Full Text] [Related]
25. Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.
Wild MK; Strittmatter W; Matzku S; Schraven B; Meuer SC
J Immunol; 1999 Aug; 163(4):2064-72. PubMed ID: 10438945
[TBL] [Abstract][Full Text] [Related]
26. Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.
Weinhold KJ; Bolognesi DP; Matthews TJ
J Natl Cancer Inst; 1985 Oct; 75(4):717-24. PubMed ID: 3862904
[TBL] [Abstract][Full Text] [Related]
27. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Tipton TR; Roghanian A; Oldham RJ; Carter MJ; Cox KL; Mockridge CI; French RR; Dahal LN; Duriez PJ; Hargreaves PG; Cragg MS; Beers SA
Blood; 2015 Mar; 125(12):1901-9. PubMed ID: 25631769
[TBL] [Abstract][Full Text] [Related]
28. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.
Shiokawa M; Takahashi T; Murakami A; Kita S; Ito M; Sugamura K; Ishii N
Biochem Biophys Res Commun; 2010 Sep; 399(4):733-7. PubMed ID: 20696130
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
30. Human IgG1 and mouse IgG3 but not monomeric IgM or IgE facilitate antibody-dependent cell-mediated cytotoxicity by human natural killer cells.
Shenoy AM; Brahmi Z
Nat Immun Cell Growth Regul; 1989; 8(6):338-48. PubMed ID: 2622463
[TBL] [Abstract][Full Text] [Related]
31. Immunoregulatory role of Ig isotypes. I. Induction of contrasuppressor T cells for contact sensitivity responses by antibodies of the IgM, IgG1, and IgG3 isotypes.
Ptak W; Flood PM; Janeway CA; Marcinkiewicz J; Green DR
J Immunol; 1988 Aug; 141(3):756-64. PubMed ID: 2456332
[TBL] [Abstract][Full Text] [Related]
32. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
[TBL] [Abstract][Full Text] [Related]
33. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
Dennert G; Anderson CG; Warner J
J Immunol; 1986 Jun; 136(11):3981-6. PubMed ID: 3517162
[TBL] [Abstract][Full Text] [Related]
34. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
Christiaansen JE; Sears DW
Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
[TBL] [Abstract][Full Text] [Related]
35. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
37. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
Bright RK; Shearer MH; Kennedy RC
J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411
[TBL] [Abstract][Full Text] [Related]
38. Natural cytotoxicity against mouse hepatitis virus-infected target cells. I. Correlation of cytotoxicity with virus binding to leukocytes.
Holmes KV; Welsh RM; Haspel MV
J Immunol; 1986 Feb; 136(4):1446-53. PubMed ID: 3003198
[TBL] [Abstract][Full Text] [Related]
39. The effect of NK cell activation by tumor cells on antigen-specific antibody responses.
Koh CY; Yuan D
J Immunol; 1997 Nov; 159(10):4745-52. PubMed ID: 9366398
[TBL] [Abstract][Full Text] [Related]
40. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]